A study with three years of follow-up shows that the drug stays effective and safe for most, although 16% stopped getting treated with Dupixent, mainly because it was ineffective or caused side effects.
News|Articles|February 16, 2024
Japan Approves Dupixent for Chronic Spontaneous Urticaria (CSU) Becoming First in the World to Do So
Author(s)Logan Lutton
This makes CSU treatment the sixth approved use globally.
Advertisement
The Ministry of Health, Labor and Welfare (MHLW) in Japan granted marketing and manufacturing authorization for Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU), according to today’s Regeneron and Sanofi
CSU is characterized by recurrent and itchy hives often triggered by temperature or pressure on the skin. Both adults and children can be affected but it is twice as common in adult females. It is associated with immune disorders like food allergies and hypothyroidism.
About 110,000 people in Japan aged 12 years and older currently suffer from uncontrolled moderate to severe CSU. In the United States, 1% of the population is affected at any given time.
Dupixent is also used to treat atopic dermatitis and asthma with 800,000 being treated globally.
Advertisement
Related to this article
Elevated levels of immunoglobulin G (IgG) drive “inflammaging” processes that take a toll on skin tissue as people age, according to research results reported by Japanese researchers. Reducing IgG may mitigate the loss of collagen and elastin.
Low birth volume fuels rural healthcare obstetric closures, limiting women’s health access—see which hospitals are most at risk.
In both mice and human cells, a small molecule selectively blocked the activity of MAP4K4, a protein involved in several major biological pathways.
Steering claims away from 340B-eligible pharmacies is one option but also the most disruptive, said Jeff Dunn, Pharm.D., MBA, of NeosRx.
340B discounts preclude rebates paid to pharmacy benefit managers for their payer clients. Dunn says new transparency and cost pressures have created awareness of “340B rebate erosion.”
Onswik is approved to improve glycemic control in adults with Type 2 diabetes and will be available in the United States in the coming months in two concentrations. No information is available on the list price.
A meta-analysis of 13 trials and 969 patients saw some short-term reductions in cancer-related pain and anxiety, especially during procedures, when using virtual reality.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Survey identifies what doctors and patients want from support programs
2
The Future of Employer Health Benefits Is Connected Care
3
FDA approves Lilly’s Onswik, the second once-weekly insulin
4
Virtual reality could become new treatment tool for cancer pain and anxiety, meta-analysis finds
5